Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503159 | 1.00 | HCAR2 (0.67) | HCAR2ATMPARP1SMYD3RAF1 | |
| Hydrochloric Acid SCHEMBL27809845 | 0.98 | HCAR2 (0.64) | HCAR2ATMPARP1SMYD3RAF1 | |
| SCHEMBL2841794 | 0.84 | SIRT2 (0.54) | HCAR2RAF1PKMYT1MKNK1MKNK2 | |
| SCHEMBL29477599 | 0.83 | HCAR2 (0.62) | HCAR2ATMPARP1SMYD3RAF1 | |
| SCHEMBL30892620 | 0.82 | HCAR2 (0.50) | HCAR2ATMPARP1SMYD3RAF1 | |
| Hydrazine SCHEMBL28220034 | 0.81 | HCAR2 (0.92) | HCAR2ATMSMYD3RAF1MKNK1 | |
| SCHEMBL10274533 | 0.80 | HCAR2 (0.58) | HCAR2ATMSMYD3RAF1PKMYT1 | |
| SCHEMBL12164220 | 0.80 | HCAR2 (0.58) | HCAR2ATMPARP1SMYD3RAF1 | |
| SCHEMBL3102318 | 0.80 | HCAR2 (0.69) | HCAR2ATMSMYD3MKNK1MKNK2 | |
| SCHEMBL29586507 | 0.80 | HCAR2 (1.00) | HCAR2ATMSMYD3RAF1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| CN-117157282-A | Crystalline forms of N- {3- [ (1S) -1- { [6- (3, 4-dimethoxyphenyl) pyrazin-2-yl ] amino } ethyl ] phenyl } -5-methylpyridine-3-carboxamide and related products and methods | GB002股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| CN-111601790-B | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| CN-105348185-B | Bicyclic [3.2.1] octyl group amide derivatives and application thereof | H.隆德贝克有限公司 | 2018-02-16 | — | — | CN | claimed |
| CN-206198963-U | A kind of waste gas centralized processor in β nicotinamide mononucleotides production technology | 浙江邦成化工有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-105348185-A | Bicyclo[3.2.1]octyl amide derivatives and uses of same | LUNDBECK & CO AS H | 2016-02-24 | — | — | CN | claimed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20050014268-A1 | Genetic transformation using a PARP inhibitor | BAYER BIOSCIENCE NV | 2005-01-20 | — | — | US | claimed |
| EP-1496125-A2 | Genetic transformation using a PARP inhibitor | Bayer BioScience N.V. (BE) | 2005-01-12 | — | — | EP | claimed |
| US-20030175925-A1 | Nucleic acids; genetic engineering; insertion into cells; modulate antibodies | DEUTSCHE EFFECTEN- UND WECHSEL-BETEILIGUNGSGESELLSCHAFT AG (DE) | 2003-09-18 | — | — | US | claimed |
| US-6074876-A | PREPARING TRANSGENIC PLANT CELLS USING POLY ADENINE DIPHOSPHATE POLYMERASE; CONTACTING PLANT CELLS WITH ENZYME INHIBITOR, CONTACTING PLANT CELLS WITH A EXOGENOUS NUCLEOTIDE SEQUENCES, RECOVERING TRANSGENIC PLANT CELLS | PLANT GENETIC SYSTEMS, N.V. (BE) | 2000-06-13 | — | — | US | claimed |
| EP-0641193-A4 | CHEMOTHERAPEUTIC DRUG COMBINATIONS. | MARTIN DANIEL S (US) | 1995-09-06 | — | — | EP | claimed |
| EP-0641193-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | PRO-NEURON, INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023014-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | MARTIN DANIEL S (US) | 1993-11-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | HCAR2 4212/4885ATM 3839/4885PARP1 1780/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HCAR2 2549/4885ATM 4121/4885PARP1 4079/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | HCAR2 50/4885ATM 4459/4885PARP1 2286/4885 |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | HCAR2 975/4885ATM 3233/4885PARP1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.